Compare DNP & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNP | TMDX |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | N/A | 2019 |
| Metric | DNP | TMDX |
|---|---|---|
| Price | $10.05 | $136.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $133.00 |
| AVG Volume (30 Days) | 479.6K | ★ 835.5K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | ★ 170.70 |
| EPS | 2.30 | ★ 2.54 |
| Revenue | $154,887,179.00 | ★ $566,354,000.00 |
| Revenue This Year | N/A | $38.84 |
| Revenue Next Year | N/A | $20.43 |
| P/E Ratio | ★ $4.26 | $53.83 |
| Revenue Growth | 3.30 | ★ 41.20 |
| 52 Week Low | $8.69 | $55.00 |
| 52 Week High | $10.04 | $156.00 |
| Indicator | DNP | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 54.31 |
| Support Level | $10.00 | $133.50 |
| Resistance Level | $10.35 | $156.00 |
| Average True Range (ATR) | 0.11 | 8.50 |
| MACD | -0.02 | 0.41 |
| Stochastic Oscillator | 14.29 | 55.98 |
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.